Genomics services company Caprion-HistoGeneX said on Thursday that it will expand its global capabilities to address the emerging needs for therapeutic and prophylactic solutions aimed at developing vaccines and other therapies for infectious diseases including COVID-19 under a new strategic partnership with Viroclinics-DDL.
The combined expertise of both the companies allows for a seamless, integrated service experience for customers worldwide, with a broad service offering covering all stages of vaccine and antiviral development, ranging from preclinical and in-vitro research models to the deployment of custom-developed and off-the-shelf functional assays for monitoring vaccine efficacy.
Based on the specialized platforms of viral neutralization, flow cytometry, ELISpot and immuno-assays, the partnership will provide access to an extended global network of clinical sample processing facilities across North America, South America, Europe, Africa and Asia, along with operational and logistical services including sample management and sampling kits.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients